Overview

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Anti-Inflammatory Agents, Non-Steroidal
Esomeprazole